IHH subsidiary sues Japanese pharma company over Fortis Malar deal

The IHH unit is seeking to claim damages of JPY20b from the Japanese company.

Northern TK Venture, an indirect wholly owned subsidiary of IHH Healthcare, has filed a lawsuit against Japanese pharmaceutical company, Daiichi Sankyo for allegedly preventing them from proceeding with open offers to buy a stake at India’s Fortis Healthcare.

In a bourse filing, SGX-listed IHH Healthcare said its subsidiary filed a JPY20b claim against Daiichi Sankyo at the Tokyo District Court for causing losses to the former.

Under the lawsuit filed by NTK, Daiichi Sankyo will have to pay JPY20b with interest of 3% per annum.

“NTK is also seeking an injunction to prevent Daiichi Sankyo from making defamatory remarks against NTK concerning the open offers,” IHH Healthcare stated.

“The claims filed by NTK against Daiichi Sankyo are tort claims premised on the latter’s unlawful interference with NTK’s trade or business, conspiracy of Daiichi Sankyo and other persons, malicious falsehood and defamation under the applicable substantive laws,” the company added.

Follow the link for more news on

IHH Healthcare

Also Read

Singaporeans' physical well-being at highest level since 2019

SingHealth partners with OutcomesAI to integrate AI into medical workflows

Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

I want to download the media kit